Loading
Prostate Cancer Treatment and Research / Prostate Cancer Diagnosis and Treatment / Economic and Financial Impacts of Cancer · Journal article
JAMA Network Open · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a descriptive analysis of inflation-adjusted prostate cancer spending trends in Medicare beneficiaries from 2012 to 2021, documenting a nearly fourfold increase in total expenditure and a marked shift from radiotherapy and surgery toward systemic therapy. The data document composition and magnitude of spending changes but do not establish causation, comparative effectiveness, or clinical value of these expenditure patterns.
Population-level descriptive economic evaluation. Fee-for-service Medicare beneficiaries (n=1,231,567 at diagnosis) with histologically confirmed prostate adenocarcinoma and prostate cancer–related claims; mean age 73.2 (SD 7.7) years.. Intervention: None; observational analysis of spending patterns by calendar year and service category. n = 1,231,567. United States (SEER-Medicare linked data).
Aggregate prostate cancer–related expenditures increased from $504 million in 2012 to $1.9 billion in 2021 Systemic therapy spending increased from $142 million (28.1%) in 2012 to $1.4 billion (74.0%) in 2021 By 2021, second-generation androgen receptor–targeted therapy accounted for $1.2 billion (86.6% of systemic therapy spending and 64.0% of total prostate cancer–related expenditures)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and health care administrators should recognize that systemic therapy now dominates prostate cancer spending in Medicare; this trend reflects clinical practice evolution but the data do not indicate whether this spending shift improves outcomes or represents sustainable value. Further analysis linking expenditure patterns to clinical outcomes and quality measures would be needed to guide resource allocation decisions.
A descriptive economic analysis of spending patterns using administrative data; documents trends but lacks comparative design, causal inference, or clinical outcomes to support practice change.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and health care administrators should recognize that systemic therapy now dominates prostate cancer spending in Medicare; this trend reflects clinical practice evolution but the data do not indicate whether this spending shift improves outcomes or represents sustainable value. Further analysis linking expenditure patterns to clinical outcomes and quality measures would be needed to guide resource allocation decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Importance Prostate cancer care has evolved substantially during the past decade, with increasing use of systemic therapies across the disease spectrum. How these changes have affected the composition of spending for prostate cancer–related health care remains incompletely characterized. Objective To evaluate temporal trends in prostate cancer–related health care expenditures and identify the major components of care accounting for changes in spending from 2012 to 2021. Design, Setting, and Participants This population-level economic evaluation used Surveillance, Epidemiology, and End Results (SEER)–Medicare linked data from January 1, 2012, to December 31, 2021. The analysis was performed in January 2026. Participants included fee-for-service Medicare beneficiaries with histologically confirmed prostate adenocarcinoma and prostate cancer–related claims during the study period. Exposures Calendar year and category of services for prostate cancer–related health care. Main Outcomes and Measures Annual aggregate prostate cancer–related Medicare expenditures were inflation-adjusted to 2017 US dollars and categorized by radiotherapy, surgery, cryotherapy and/or high-intensity focused ultrasonography, systemic therapy, and diagnostic and monitoring services. Systemic therapy expenditures were further categorized as first-generation androgen deprivation therapy, second-generation androgen receptor–targeted therapy, and other systemic therapies. Results In the descriptive fee-for-service cohort at diagnosis, 1 231 567 beneficiaries were included; the mean (SD) age was 73.2 (7.7) years. Aggregate prostate cancer–related expenditures increased from $504 million in 2012 to $1.9 billion in 2021. Radiotherapy accounted for $227 million (45.0%) in 2012 and $228 million (12.0%) in 2021, reflecting relatively stable absolute expenditures but a declining share of total spending. Surgery accounted for $53 million (10.5%) in 2012 and $67 million (3.5%) in 2021. In contrast, systemic therapy spending increased from $142 million (28.1%) in 2012 to $1.4 billion (74.0%) in 2021. By 2021, second-generation androgen receptor–targeted therapy accounted for $1.2 billion (86.6% of systemic therapy spending and 64.0% of total prostate cancer–related expenditures). Conclusions and Relevance In this economic evaluation of SEER-Medicare data, spending for prostate cancer–related health care increased substantially from 2012 to 2021, with a marked shift toward systemic therapy. These findings suggest that prolonged systemic treatment has become a dominant component of prostate cancer spending and should be central to future discussions of health care sustainability.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.